Jaymes Fuller

Jaymes joined BMS (Celgene Cellular Therapeutics) in August of 2010 in the Developmental Quality Control group providing QC and core analytical testing support for Celgene’s allogeneic placental MSC-based cell therapy platform. Later, as part of the Analytical Research and Development organization, Jaymes led and contributed to analytical strategy and development of identity, potency, and cell vitality-based release and characterization methods across product platforms including allogeneic and autologous-based cell therapies as well as tissue-derived products. This body of work included supporting development and U.S. approval of the first-in-class BCMA-targeting CAR T cell therapy, Abecma, for the treatment of late stage multiple myeloma.

In his current role, Jaymes leads a team of scientists and engineers focused on building knowledge related to elucidation of mechanisms of action and identification of critical quality attributes for cell therapy products across BMS’ pipeline.